Kaneider Nicole C, Leger Andrew J, Agarwal Anika, Nguyen Nga, Perides George, Derian Claudia, Covic Lidija, Kuliopulos Athan
Departments of Medicine and Biochemistry, Molecular Oncology Research Institute, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Nat Immunol. 2007 Dec;8(12):1303-12. doi: 10.1038/ni1525. Epub 2007 Oct 28.
Sepsis is a deadly disease characterized by considerable derangement of the proinflammatory, anti-inflammatory and coagulation responses. Protease-activated receptor 1 (PAR1), an important regulator of endothelial barrier function and blood coagulation, has been proposed to be involved in the lethal sequelae of sepsis, but it is unknown whether activation of PAR1 is beneficial or harmful. Using a cell-penetrating peptide (pepducin) approach, we provide evidence that PAR1 switched from being a vascular-disruptive receptor to a vascular-protective receptor during the progression of sepsis in mice. Unexpectedly, we found that the protective effects of PAR1 required transactivation of PAR2 signaling pathways. Our results suggest therapeutics that selectively activate PAR1-PAR2 complexes may be beneficial in the treatment of sepsis.
脓毒症是一种致命疾病,其特征为促炎、抗炎和凝血反应出现严重紊乱。蛋白酶激活受体1(PAR1)是内皮屏障功能和血液凝固的重要调节因子,有人提出它参与了脓毒症的致死性后遗症,但PAR1的激活是有益还是有害尚不清楚。通过细胞穿透肽(pepducin)方法,我们提供了证据表明,在小鼠脓毒症进展过程中,PAR1从血管破坏受体转变为血管保护受体。出乎意料的是,我们发现PAR1的保护作用需要PAR2信号通路的反式激活。我们的结果表明,选择性激活PAR1 - PAR2复合物的疗法可能对脓毒症治疗有益。